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Abstract Pharmacotherapy provides an adjunct to beha-
viour modification in the management of obesity. There are
a number of new drug therapies purportedly targeting
appetite; liraglutide, and bupropion/naltrexone, which are
European Medicines Agency and US Food and Drug
Administration (FDA) approved, and lorcaserin and phen-
termine/topiramate, which have FDA approval only. Each
of the six drugs, used singly or in combination, has distinct
pharmacological, and presumably distinct behavioural,
mechanisms of action, thus the potential to provide defined
therapeutic options to personalise the management of
obesity. Yet, with regard to pharmacotherapy for obesity,
we are far from true personalised medicine. We review the
limited mechanistic data with four mono and combination
pharmacotherapies, to assess the potential for tailoring their
use to target specific obesogenic behaviours. Potential
treatment options are considered, but in the absence of
adequate research in respect to effects of these drugs on
eating behaviour, neural activity and psychological sub-
strates that underlie poorly controlled eating, we are far
from definitive therapeutic recommendations. Specific
mechanistic studies and broader behavioural phenotyping,
possibly in conjunction with pharmacogenetic research, are
required to characterise responders for distinct pharma-
cotherapeutic options.
Keywords Pharmacotherapy  Obesity  Eating behaviour 
Appetite  Reward  Inhibitory control  Personalised
Medicine
Introduction
The global obesity pandemic is a primary public health
concern, due to prevalence (600 million obese, BMI C 30,
within a wider population of 1.9 billion overweight adults
according to WHO), and the impact excess body weight
has on physical, psychological and economic quality of life
[1]. In the UK, the annual cost of obesity to the NHS is an
estimated £5.1 billion, whilst total cost to the wider econ-
omy is an estimated £27 billion [2]. Therefore, effective
measures to tackle the burden of obesity, and obesity
related diseases, are essential.
Reducing energy intake through changes in eating
behaviour, and increasing daily activity, help maintain the
state of negative energy balance required to lose weight.
These are the principle components of obesity treatment
and demand fundamental and sustained behavioural
change. In the context of intervention, there are two key
barriers to behaviour change; firstly, patterns of eating and
activity behaviour are shaped by lifelong learning, and
behaviour modification must tackle entrenched habit.
Secondly, even if change is achieved, maintaining healthier
behaviours in an environment that promotes weight gain
demands constant exertion. The obesogenic environment
primes individuals to relapse into their pre-intervention
behavioural repertoire. Problematically, appetite regulation
is asymmetrical [3], in that the body defends against under-
consumption irrespective of current weight status or energy
reserves.
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Appetite regulation involves an interplay between sati-
ety, inhibitory control (IC) and reward processes. The
obese have a biological vulnerability for weight gain which
is manifested in eating behaviours that lead to overcon-
sumption [4]. Blundell et al. [5] suggested a cluster of
behaviours that relate to satiety (weak satiety response,
weakened post-ingestive satiety), reward (preference for
high fat foods, strong hedonic attraction to palat-
able foods), and IC (disinhibited eating, uncontrolled
hunger) that comprise a susceptible behavioural phenotype
for obesity. Thus, regulatory control of eating is under-
mined by reduced satiety and increased responsivity to
food cues (reward driven eating). As such, IC has greater
likelihood of being overwhelmed by environmental cues to
over consume in the obese.
Calorie restriction compromises appetite control by
increasing responsivity to food cues (an effect which is
even more pronounced in overweight/obese individuals)
[6], craving [7] and preoccupation with food [8], as well as
having negative impact on mood and cognition [9].
Negative mood states can lead to reduced control of eating
and increased emotional eating [10]. Taken together, this
suggests that the obese are arguably the least capable of
coping with the consequences of dieting, as their appetite is
prior compromised, they have low control over their eating,
and often suffer with depression, impacting upon
motivation.
Heritability estimates of body weight are high. How-
ever, multiple common genetic variants belie obesity in the
general population. Recent meta-analyses suggest that 97
BMI-associated genetic loci account for under 3% of
variation in BMI [11], thus the variance of BMI explained
by any single gene is low. This suggests that a standardised
personalised medicine approach of targeting key genes
with pharmacotherapy for obesity would, on its own, be
inadequate. However, the fat mass and obesity-associated
gene (FTO) has the largest effect size of BMI-associated
genetic variants, whereby adults homozygous for the at risk
allele are approximately 3 kg heavier than those not
inheriting the at risk allele [12]. Notably, Wardle et al. [13]
found that variation in FTO is associated with diminished
satiety, and more recently satiety sensitivity was shown to
mediate part of the association between genetic risk and
adiposity [14]. Similarly variations in FTO are associated
with other adiposity-related behaviours in children;
increased food intake [15] fat consumption/consumption of
palatable food [16] and loss of control over eating [17].
Recent research in dizygotic twins from the GEMINI
population-based twin cohort suggests that appetite dif-
ferences in the first few weeks of life yield differential
weight gain from 3 to 15 months [18], and meal size is an
important driver of weight gain in early life [19]. Taken
together, these findings suggest that differences in
behaviour are critical in mediating the association between
genetic risk and obesity.
In order to personalise pharmacotherapy for obesity in
adults, it is critical that behavioural issues associated with
obesity are targeted. How does drug therapy impact appetite
(within a meal and throughout the day), portion size and the
frequency of eating (satiety)? How does it affect respon-
siveness to palatable foods, eating rate and food choice (re-
ward)? Can pharmacotherapy improve the ability to control
eating behaviour (IC)? If so, can treatment be tailored to
patients with specific problem behaviours?
Personalised therapy
Specialised adult weight management services provide per-
son-centred care, for treatment of obesity, assisting patients to
make lasting lifestyle changes. In this setting, access to dis-
tinct pharmacotherapies could well provide meaningful ben-
efits when developing individual management plans. Recent
NICE-accredited commissioning guidance for weight man-
agement clinics recommends a specialist multidisciplinary
team approach (including pharmacotherapy) for treatment of
severe obesity [20]. Pharmacotherapy has the potential to
improveweight loss outcomes in primary care and specialised
weight management services, through (1) reducing negative
psychological and biological sequelae produced by calorie
restriction, (2) aiding behaviour change and (3) improving
self-efficacy (Fig. 1). However, the development of a per-
sonalised approach is not possible without guidance from
patient experience about personal barriers to behaviour
change. In addition, pharmacogenetic and mechanistic stud-
ies, which identify drug effects on eating behaviour, IC, and
reward processing, would allow characterisation of successful
responders to different treatments.
Here, we review the available data assessing behaviour
and neurophysiology modification with the four most
recently available (FDA approved) mono and combination
pharmacotherapies for obesity. Whilst orlistat (Xenical)
has been approved as a pharmacological intervention for
obesity since 1998, this is not a centrally acting drug and is
not regarded as having direct behavioural effects (although
its side effect profile may modify food choice and
encourage adherence to a low fat diet) relating to satiety,
inhibitory control or reward responsivity, for these reasons
it has not been included in this review.
Liraglutide (Saxenda)
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor
agonist with long-lasting biological activities (half-life of
10–14 h) in comparison with endogenous GLP-1 which is
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rapidly degraded by the enzyme dipeptidyl peptidase-IV
(DPP-IV). Liraglutide is approved for treatment of T2DM
at the 1.8 mg dose, and recently attained FDA (2014) and
EMA (2015) approval for use as a weight loss therapy at
the 3.0 mg injectable dose.
Mechanism of action
Endogenous GLP-1 is secreted from L endocrine cells in
the intestine in response to intraluminal nutrients and
stimulates GLP-1 receptors located on pancreatic beta
cells, to promote glucose-dependent insulin secretion [21].
GLP-1 is therefore recognised as an incretin hormone.
GLP-1 is also synthesised in the nucleus tractus solitarius
(NTS) of the brainstem and acts as a neurotransmitter
projecting to feeding relevant hindbrain, midbrain and
forebrain regions. The central actions of gut-derived and
brain-derived GLP-1 may be separable. Due to the rapid
degradation of gut-derived GLP-1 by DPP-IV, GLP-1
contributes a neuroincretin effect via a neural pathway
composed of vagal afferents in the intestine and hepatic
portal, and not by crossing the blood brain barrier (BBB)
[22]. Knockdown of vagal afferent neuron GLP-1Rs
increases meal size and accelerates gastric emptying, as
well as producing elevated post-meal glycaemia and
reduced insulin, highlighting the neuroincretin and satiety
effects of gut-derived GLP-1 [23].
Long-lasting GLP-1R agonists, such as liraglutide, are
DPP-IV resistant, remain stable following peripheral
administration and can have central effects from crossing
the BBB as well as via vagal afferents. As such,
liraglutide exhibits pleiotropic effects which extend
beyond the incretin action of gut-derived GLP-1 [22], via
action at central GLP-1R. This is supported by pre-
clinical evidence that vagotomy only partially blocks
intake suppression following intraperitoneal liraglutide
injection [24].
Peripherally administered liraglutide has been observed
to act directly on POMC neurons in the arcuate nucleus of
the hypothalamus [25], to suppress feeding. Moreover,
central GLP-1Rs are also located in the mesolimbic reward
system, e.g. the ventral tegmental area (VTA), and nucleus
accumbens [26]. Thus, liraglutide may also influence
reward-motivated eating and reduce intake through effects
on central appetite and reward neural pathways, as well as
peripheral gastrointestinal sites.
Fig. 1 Mitigating effects of pharmacotherapy on calorie restriction
and negative sequelae. Dieting increases hunger and food cue
responsiveness, which undermines inhibitory control and other
executive functions and in turn, the ability to cope and maintain the
diet (self-efficacy). Dieting also has negative effects on mood which
reduce self-efficacy for controlling behaviour and reintroduce food-
related coping strategies. Negative mood state also reduces inhibitory
control and other executive functions producing a cycle whereby
ability to control behaviour and self-efficacy is undermined. However,
anti-obesity drugs can mitigate some of the effects of dieting by
reducing hunger and food cue responsiveness, leading to improved
inhibitory control and maintained executive function, which improves
self-efficacy and the ability to maintain calorie restriction. Mitigating
effects on mood are also boosted by improved coping and self-
efficacy, as well as by observing improved weight loss
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Efficacy, effects on behaviour and tailoring potential
Human data on the efficacy of liraglutide for weight loss
come from the Satiety and Clinical Adiposity–Liraglutide
Evidence (SCALE) studies. These studies suggest liraglu-
tide 3.0 mg is effective at reversing prediabetes and pro-
ducing weight loss. A meta-analysis of three studies, with a
total of 2921 patients receiving liraglutide and 1503
receiving placebo, suggests 5.2 kg additional weight loss
and an OR of 5.54 for achieving 5% weight loss with
liraglutide relative to placebo [27].
Short-term liraglutide treatment (20.0 ± 6.4 days) at
low doses (0.3–0.9 mg per day) can reduce staple food
intake (but not non-staple food intake) and feelings of
hunger, compared to other oral glucose lowering medica-
tion [28]. Reductions in hunger along with reduced dura-
tion of eating during an ad libitum buffet were reported
with liraglutide (1.8 mg dose), relative to placebo and
glimepiride (oral sulfonylurea used as an active control to
discriminate appetite and glycaemic control effects) in
overweight/obese (BMI 27–40 kg/m2) males and females
with T2DM [29]. Nevertheless, there was no reduction in
total energy nor macronutrient intake. However, an 18%
reduction in energy intake at an ad libitum buffet lunch
meal, accompanied by lower postprandial hunger, with
liraglutide (1.8 mg) compared to placebo, was reported in
another sample of males and females (BMI
29.7 ± 4.2 kg/m2) with T2DM. No change in macronu-
trient composition or meal duration was seen [30]. Taken
together, these data suggest that even at sub-therapeutic
doses for weight management, there is consistent evidence
of drug effects on satiety in a population generally over-
weight or obese, albeit all with T2DM.
Using both 3.0 and 1.8 mg doses in non-diabetic adults,
van Can et al. [31] observed that both doses produced
*16% reduction in food intake in an ad libitum lunch meal
relative to placebo (5 h post-fixed load breakfast). Post-
meal satiety and fullness ratings were significantly
increased in both liraglutide groups versus placebo, and
prospective consumption was significantly reduced. The
3.0 mg dose also delayed gastric emptying 1 h post-
breakfast compared to placebo. Twenty-four hour energy
expenditure was reduced in liraglutide treatment groups
relative to the control; this pattern of results suggests that
weight loss with liraglutide is produced by reductions in
food intake and increased satiety rather than changes in
energy expenditure.
With regard to central mechanisms, Farr et al. [32]
reported decreased parietal activation in response to
rewarding food images following 17 days of liraglutide
treatment (0.6 mg for 7 days, 1.2 mg for 7 days and
1.8 mg for 3 days) versus placebo, in obese patients with
T2DM, tested in the fasted state. It was argued this reflects
an attenuation of appeal of energy dense foods. Moreover,
reduced parietal activation to palatable foods was corre-
lated with ratings of how pleasant participants would find
eating. However, the sample size was small (n = 18) so
findings should be treated with caution (see [33]). IC was
assessed (out of the scanner using Stop Signal and Go/No-
Go Tasks), but no effects of liraglutide were found.
However, during the fasted state, liraglutide significantly
reduced hunger ratings relative to placebo, and daily
energy intake was significantly reduced at 1.8 mg liraglu-
tide vs placebo (although how this was assessed is not
reported).
Liraglutide, therefore, appears to produce weight loss
through homoeostatic mechanisms that boost satiety,
leading to reduced intake. However, more data are needed
with the 3.0 mg dose in non-T2DM samples to characterise
effects on the interplay between satiety, reward and IC.
Bupropion/Naltrexone (Contrave)
The combination therapy of the catecholamine reuptake
inhibitor bupropion (360 mg/day) and opioid antagonist
naltrexone (32 mg/day) (Table 1) is approved for the
management of obesity in sustained release form by the
FDA and the EMA. Bupropion is an atypical antidepres-
sant, which is currently used in smoking cessation to
reduce craving and ease withdrawal [34]. In addition,
bupropion also has an observable anorexigenic effect.
Clinical trials investigating bupropion as a monotherapy
demonstrate modest weight loss [35, 36]. Naltrexone has
also been investigated as monotherapy for obesity, but
although it affects food choice and palatability, it is not
associated with weight loss [37]. Nevertheless, naltrex-
one’s potential to reduce reward sensitivity to palat-
able food may be beneficial in a combined therapy.
Mechanism of action
Pre-clinical studies demonstrate the bupropion/naltrexone
combination acts on POMC neurons, critical components
in the integration of episodic and tonic signals of energy
intake and energy storage (expressing both serotonin and
leptin receptors). Bupropion stimulates the release of the
MC4R agonist aMSH from the POMC neurons in the PVN.
The POMC neuron itself is regulated by endogenous opi-
oids via opioid-mediated negative feedback. Naltrexone
blocks the inhibitory action of b-endorphin preventing the
cessation of bupropion-induced activation [38]. Due to the
key role of POMC neurons in integrating and relaying
peripheral satiety signals, it is hypothesised bupropion/
naltrexone reduces hunger by strengthening within-meal
satiation and post-meal satiety.
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Efficacy, effects on behaviour and tailoring potential
Efficacy of bupropion/naltrexone to produce weight loss in
overweight or obese adults has been assessed in the Con-
trave Obesity Research (COR) phase III clinical trials [
[39]–[41]—see Table 2]. Meta-analysis suggests 5.0 kg
additional weight loss and an OR of 3.96 for achieving 5%
weight loss with bupropion/naltrexone relative to placebo
(n = 2044 vs. 1319 over four studies) [27].
Appetitive traits were assessed using self-report mea-
sures in these trials. In COR-I [39] bupropion/naltrexone
produced improvements on selected items in the Control
of Eating Questionnaire (COEQ), namely increased
fullness, reduced hunger (satiety effects), reduced desire
for sweet, non-sweet or starchy foods (reward effects),
increased ability to control eating and resist food crav-
ings (craving control). Similarly naltrexone/bupropion-
treated patients in COR-II [40] report increased ability to
resist cravings and control eating, as well as reduced
frequency of food craving (as measured by COEQ) again
suggesting effects on reward and control (if not satiety)
at week 56. No differences in cravings were found on
any subscale of the Food Craving Inventory (FCI)
between bupropion/naltrexone and placebo in COR-I and
COR-BMOD. It is likely that these inconsistencies are
the result of the properties of the scales. Specifically the
items COEQ relating to craving refer to the ability to
control/resist cravings, whereas the items on the FCI
relate more to changes in cravings (i.e. preferences for
specific foods) perhaps reflecting that this drug combi-
nation may not have strong effects on food choice.
Indeed, this highlights the importance of clearly opera-
tionalising craving assessments from the outset of trials.
Overall, across these studies self-report data suggest
effects on satiety, reward and/or craving control;
however, appropriate direct assessments of drug effects
on appetite and behaviour are lacking.
There are no clinical experimental data available for the
effects of bupropion/naltrexone effects on eating beha-
viour. However, fMRI data suggest the combination ther-
apy may be useful for improving control of eating [42].
Specifically, bupropion/naltrexone reduced hypothalamic
(satiety) activity and increased anterior cingulate activity
(IC) in response to food cues. However, without beha-
vioural correlates and further mechanistic data, the sug-
gestion of improved control remains speculative.
Lorcaserin (Belviq)
The selective 5HT2C receptor agonist lorcaserin is
approved in oral form in the USA (FDA) for long-term
weight management in the obese and overweight. Under
the trade name Belviq (Arena Pharmaceuticals, San Diego,
CA) it is available at the 10 mg BID dose and as Belviq XR
at the 20 mg QD dose.
Mechanism of action
Lorcaserin is understood to reduce food intake by its
activation of 5-HT via POMC neurons, importantly this
drug is selective for the 5-HT2C receptor, with little
affinity for the 2A and 2B receptor subtypes. This limits the
psychological and cardiovascular side effects observed
with non-selective serotonergic drugs previously approved,
then withdrawn, e.g. fenfluramine and sibutramine [43].
Stimulation of 5-HT2C receptors leads to stimulation of
POMC in the arcuate nucleus, and aMSH is produced from
POMC neurons and acts on MC4R which results in food
intake reduction in pre-clinical studies [44].
Table 1 Mechanism of action and effect on appetite expression, eating behaviour and CNS activity for weight loss pharmacotherapies
Drug Mechanism of action Effect on appetite expression, eating behaviour or CNS
activity
Liraglutide GLP-1 receptor agonist Reduced intake, reduced post-meal hunger, increased post-
meal satiety and fullness. Reduced CNS reward activity
Bupropion/naltrexone Dopamine and norepinephrine reuptake
inhibitor?opioid (mu and k) receptor antagonist
Increased fullness, reduced hunger, reduced desire for sweet,
non-sweet or starchy foods, increased ability to control
eating and resist craving. Increased activity in inhibitory
control-related areas (anterior cingulate), reduced activity
in hypothalamus
Lorcaserin Selective 5HT2C receptor agonist Reduced food intake, decreased hunger, decreased activity in
attention-related neural regions (parietal and visual
cortices), reduced emotional and salience related limbic
activity (insula and amygdala)
Phentermine/topiramate TAAR1 agonist and norepinephrine releasing
agent?sulphamate-substituted monosaccharide with
action on GABA signalling
No published data
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Efficacy, effects on behaviour and tailoring potential
Weight loss with lorcaserin has been assessed in the
Behavioural Modification and Lorcaserin for Overweight
and Obesity Management (BLOOM; 3182 obese or over-
weight patients receiving lorcaserin 10 mg, or placebo,
twice daily–Smith et al. 2010) [45], BLOOM-DM (604
overweight or obese T2DM patients receiving lorcaserin
10 mg once daily, twice daily or placebo) [46] and Beha-
vioural Modification and Lorcaserin Second Study for
Obesity Management (BLOSSOM; 4008 obese or over-
weight patients receiving 10 mg once daily, twice daily or
placebo) [47] clinical trials. Meta-analysis suggests 3.2 kg
additional weight loss and an OR of 3.10 for achieving 5%
weight loss with lorcaserin relative to placebo (n = 3350
vs. 3288 over three studies) [27].
Martin et al. [48] assessed energy intake and expendi-
ture in overweight/obese participants, following lorcaserin
treatment over a 56-day period, in a double-blind, ran-
domised, placebo-controlled trail. At 56 days lorcaserin
treatment resulted in significantly reduced energy intake at
lunch and dinner in ad libitum buffet meals compared to
baseline measures, as well as a significantly larger reduc-
tion in energy intake compared to placebo. Reductions in
energy intake correlated with reductions in body weight.
However, energy expenditure, substrate oxidation and
activity levels were not affected by lorcaserin, suggesting
that weight loss occurs through reduced energy intake
alone. Notably, lorcaserin produced significant decreases in
perceived hunger, with no effect on food cravings, body
image, dietary restraint and disinhibition.
Lorcaserin effects on BOLD response to food cues have
been assessed in a randomised, placebo-controlled trial
[49]. Participants were assigned to lorcaserin or placebo
conditions and undertook fMRI scans at baseline (pre-
drug), one week, two weeks and four weeks in both fasted
and fed states. At baseline, there were no between-group
differences in neuronal activation. Following one week of
treatment the lorcaserin group showed reduced activity in
attention-related parietal and visual cortices, to highly
desirable food cues, compared to baseline in the fasted
state (although this effect was attenuated by week four).
Nevertheless, in the fed state, compared to baseline, four
weeks of lorcaserin treatment, led to reductions in parietal
cortex activation, for all food images relative to non-food
images—accompanied by modest weight loss. The authors
argue that highly palatable foods become less important to
patients receiving lorcaserin due to reduced activation in
areas associated with attention and salience. IC was
assessed using a Stop Signal Task, with no between-group
differences, nor any within group differences over time. A
whole-brain analysis of baseline activity suggested that
amygdala activation in response to highly palatable food
cues predicted greater weight loss at four weeks with lor-
caserin. Similarly, baseline amygdala and occipital acti-
vation to highly palatable food in a fed state predicted
reduced BMI with lorcaserin after four weeks. Thus, lor-
caserin may be beneficial to patients who have high food
cue reactivity, or are emotional eaters; however, without
confirmatory subjective and behavioural data this remains
speculative.
More data are needed to fully characterise lorcaserin
effects on eating behaviour. However, these two studies
tentatively suggest lorcaserin has a modest effect on
appetite leading to reduced energy intake and perceived
hunger, as well as reduced salience of rewarding food cues.
However, there are no behavioural data available to assess
impact on reward-motivated, or poorly controlled eating.
Whilst IC has been assessed experimentally, with no evi-
dence that lorcaserin increases control, the task used does
not appear to be food cue specific, which may provide a
more reliable outcome.
Phentermine/Topiramate (Qsymia)
Phentermine/topiramate extended-release is another com-
bination therapy that is FDA approved for weight man-
agement in the obese and overweight with one or more
weight related comorbidity (initial dose: phentermine
3.75 mg/topiramate 23 mg extended-release, maintenance
dose: phentermine 7.5 mg/topiramate 46 mg extended-re-
lease). Phentermine is currently approved singly for short-
term obesity management, and topiramate is used in the
treatment of epilepsy and migraine prevention [50]. The
combination of phentermine/topiramate as a pharma-
cotherapy for obesity is understood to combine lower doses
of each drug to reduce undesired cardiovascular effects
whilst having a synergistic effect on weight loss.
Mechanism of action
The atypical amphetamine derivative phentermine stimu-
lates norepinephrine release in the CNS, with limited
effects on dopamine and serotonin [51]. Its action on
norepinephrine is understood to produce its anorectic
effects. A meta-analysis [52] suggests that monotherapy
phentermine produces modest weight loss for up to
6 months. However, despite the absence of addictive
potential, due to its status as an amphetamine derivative,
phentermine is presumed to increase blood pressure and
heart rate (although there is evidence to contrary see
Hendricks et al. [53]) and thus is approved for short-term
treatment only. Topiramate is a sulphamate-substituted
monosaccharide that is widely available as an anti-con-
vulsant, with weight loss properties. The exact mechanism
Acta Diabetol (2017) 54:715–725 721
123
of action of topiramate for weight loss is unclear; never-
theless, dose-ranging studies have observed significant
weight loss over 6 months in the obese [54], as well as
significant weight loss at 60 weeks with 96, 192 and
256 mg/day (7, 9.1 and 9.7%, respectively) [55].
Efficacy, effects on behaviour and tailoring potential
Efficacy and safety of two doses of phentermine/topira-
mate were assessed in the phase III clinical trials
CONQUER (2487 overweight or obese patients receiving
placebo, once-daily phentermine 7.5 mg/topiramate
46.0 mg, or once-daily phentermine 15.0 mg/topiramate
92.0 mg) [56], SEQUEL (866 patients in continuation
study from CONQUER) [57] and EQUIP (1267 obese
patients receiving placebo, phentermine 3.75 mg/topira-
mate 23 mg extended or phentermine 15 mg/topiramate
92 mg) [50]. In a meta-analysis [27] phentermine/topi-
ramate produced the highest odds of achieving 5 and
10% weight loss compared to orlistat, liraglutide, lor-
caserin and bupropion/naltrexone (moderate confidence
in estimates) with no increased odds of adverse events
(OR of 9.22 for achieving 5% weight loss relative to
placebo). However, there are no data on how this drug
combination influences eating behaviour, or fMRI data to
provide neurophysiological correlates of behaviour. Thus,
the behavioural specificity of phentermine/topiramate
remains unknown and effects on the psychological and
motivational aspects which underlie problematic eating
behaviours have yet to be characterised. Without clear
data on how the drug effects eating behaviour it is dif-
ficult to suggest which individuals may benefit from
taking this drug and to assess its tailoring potential.
A methodological platform for assessing drug
action
Pharmacotherapy as an adjunct to reduced calorie diets and
behaviour modification may provide additional benefit for
obese people in achieving and maintaining clinically
meaningful weight loss. However, so far there are little
data to enable the link between pharmacology and real-
world therapeutic benefits, i.e. proof of concept.
Whilst there are no mechanistic data for phenter-
mine/topiramate, other reviewed studies provide tentative
evidence that liraglutide and lorcaserin produce weight loss
by reducing energy intake and increasing satiety. Other
effects are less well characterised. There are self-report
data for bupropion/naltrexone suggesting satiety, reward
and/or IC effects; however, direct assessment of behaviour
is lacking. Without appropriately designed, well-powered
mechanistic studies detailing drug effects on the substrates
of eating behaviour, the tailoring potential of these drugs
remains speculative.
Evidence for increased IC in response to bupropion/
naltrexone comes from a passive viewing fMRI paradigm.
It is difficult to translate activity in singular brain regions as
being a neurophysiological marker of IC without providing
a behavioural correlate. Passive viewing paradigms are the
only technique used in imaging experiments for pharma-
cotherapies and provide the sole neurophysiological
markers of drug effects to base personalised treatments on.
However, simple activation analyses from passive viewing
paradigms are problematic for interpretation of drug effects
(one can only make meaningful judgements about activity
enhancement of IC regions, if the activity is in association
with a task that requires an inhibitory response (see Table 3
for recommendations). If we understand appetite regulation
to be an interplay between satiety, reward and IC, then
using simple paradigms from the psychology literature that
provide behavioural correlates of these components in
combination with systems level fMRI data analysis tech-
niques (functional connectivity, dynamic causal modelling)
will provide powerful evidence to assess the mechanisms
by which anti-obesity drugs work.
In order to deliver personalised treatment with anti-
obesity medication, it is necessary to characterise drug
effects on phenotypic traits associated with increased
energy intake. However, to date eating behaviour has not
been studied in sufficient detail with current anti-obesity
drugs. A methodological platform for assessment of drug
effects on appetite regulation is provided in Table 3.
Clinical response to pharmacotherapy can vary greatly,
as such future research with anti-obesity drugs should seek
to assess sub-populations of patients who respond well to
drug treatment and are successful at losing weight. Large-
scale candidate gene association studies which identify
genetic variants associated with weight loss response to
pharmacotherapy (e.g. Li et al. [57] report genetic variation
which predicts successful response to topiramate treat-
ment) and genotyping for polymorphisms predictive of
successful outcomes (e.g. Hauner et al. [58]) will help
enable personalisation of pharmacotherapy for obesity. The
goal of pharmacogenetics is to help identify patients who
may benefit most from drug therapies and is currently
underused in drug development of anti-obesity drugs.
Similarly categorising sub-populations by behavioural risk
factors (susceptible phenotypes) and observing which
behaviour types predict successful outcomes for weight
loss with each drug therapy would be beneficial for tailored
pharmacotherapy. Genotyping data should be conducted in
parallel with neuroimaging (and molecular imaging tech-
niques that allow investigation of the brain–drug effect),
cognitive and experimental paradigms that assess IC, food
reward sensitivity and eating behaviour, to characterise
722 Acta Diabetol (2017) 54:715–725
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drug effects on appetite and to observe predictors for
successful weight loss.
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Table 3 Methodological platform for assessing drug action
Component
assessed
Specific methods As per
Behavioural measures:
Energy intake at
ad libitum meals
Satiety Measure intake at a (homogenous) lunch time meal, several hours
following a fixed load breakfast (and overnight fast)
Van Can (2014) [31]—
Liraglutide
Microstructure of eating
and eating rate
Satiety/
reward
Universal eating monitor used to measure total intake, eating rate and
within-meal measures of satiety
Halford et al. (2010)
[43]—Sibutramine
Food choice Reward Food choice (healthy/unhealthy sweet foods, healthy/unhealthy savoury
foods, fatty foods) at ad libitum buffet meals can be assessed to see if
drugs modify food choice for more palatable ingesta (reward driven
eating). Macronutrient content of consumed food can be calculated
Martin et al. (2010)
[48]—Lorcaserin
Visual probe with
concurrent eye
tracking
Reward Visual probe assesses attentional bias/incentive salience of rewarding
stimuli. This can be assessed with food specific cues. Using eye tracking
can give an implicit measure of attentional bias to rewarding foods
Nijs et al. (2010) [6]
Cue specific inhibitory
control task
Inhibitory
control
Food-cue-specific inhibitory control task Houben et al. (2014)
[59]
Subjective measures:
Satiety VAS Satiety Hunger, fullness, prospective consumption, desire to eat—100 ml VAS at
hourly intervals to assess fluctuations in appetite throughout the day
Halford et al. (2010)
[43] Sibutramine
Change in expected
Satiety
Satiety Food portions shown to patient who is asked to indicate how satiating they
think it would be
Brunstrom et al.
(2008) [60]
Satiety quotient Satiety Pre-meal hunger—post-meal hunger, divided by amount consumed. A
measurement of satiating properties of a meal
Halford et al. (2010)
[43] Sibutramine
Control of eating
questionnaire
Reward/
inhibitory
control
COEQ—1) general food craving, 2) craving for sweet, 3) craving for
savoury, 4) control over appetite
Greenway et al. (2010)
[39] Bupropion/
naltrexone
Power of food Inhibitory
control
A tool developed to assess effects of obesity treatments on feelings of being
controlled by food
Capelleri et al. (2009)
[61]
Dutch eating Behaviour
questionnaire (DEBQ)
Inhibitory
control
External, emotional and restrained eating patterns De Boer et al. (2016)
[62] Liraglutide
The mindful eating scale Inhibitory
control
Key environment stimuli associated with reduced control of eating Framson et al. (2009)
[63]
Physiological and neurophysiological measures:
fMRI Satiety Activity in response to food cues in fed and fasted states Farr et al. (2016) [32]
Liraglutide 1.8 mg
fMRI—reward system Reward Activity and functional connectivity of reward system during receipt of
palatable tastes (e.g. chocolate milk)
Van Bloemendall et al.
(2014) [64]
Exenetide
fMRI—inhibitory
control pathway
Inhibitory
control
Activity/functional connectivity analysis of brain regions active during
inhibition, using food cue specific inhibitory control task
Batterink et al. (2010)
[65]
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